Outcomes of Micropulse Transscleral Cyclophotocoagulation in Uncontrolled Glaucoma Patients

Abstract

MP-TSCPC is an efficient noninvasive glaucoma treatment that achieves sustained IOP reduction and reduced need for ocular antihypertensive medications for up to 15 months. The optimal laser parameters to achieve the best success rate with the least side effects still need to be determined.